New drugs: approval, benefit assessment, coverage
The first preoccupation with the question as to how a new drug reaches patients can be confusing: What is the point of a benefit assessment if the efficacy of a drug has already been evaluated during drug development and approval? Who decides on coverage and who sets the prices? Is the procedure the same in all of Europe as it is in Germany? And in the USA? The texts and graphs in this issue of "In focus" are designed to help you get started.
1. Drug approval and early benefit assessment in Germany
2. Drug approval and benefit assessment in other countries
3. The AMNOG procedure: more than just cost control
